Antimicrobial resistance is outpacing the industry’s efforts to fight it, report finds

The article focuses on the report’s finding that the antimicrobial pipeline has shrunk since the last Benchmark was published in 2021 – falling from 92 to 60 projects over the five-year period. It also highlights the fact that children and people living in low- and middle-income countries are especially vulnerable to drug-resistant infections.

Jayasree K. Iyer, CEO at Access to Medicine Foundation is quoted: “The need for new antibiotics has never been greater... Without significant change, AMR will cause a devastating rise in deaths from preventable infections over the next two decades, with vulnerable populations living in poorer countries hit the hardest.”

Highlighting bright spots from the report, the article also noted the seven innovative that are in late-stage development – three being developed by large research-based companies and four by small- and medium-sized enterprises.